The Molecular Cancer Therapeutics (MCT) Program's long-term goal is the development of safer and more effective cancer treatments. Program members conduct basic, translational and clinical research and commonly use molecular, biological and pharmacologic tools to perform analysis of pathways intrinsic to cancer therapeutics, with emphasis on angiogenesis, receptor-mediated signaling, apoptosis, epigenetics and transcriptional interference. Our members interact with members in the Tumor Cell Biology, Cancer Genetics and Epidemiology programs and are encouraged to collaborate with other basic and clinical researchers as well as pharmaceutical industry. The main scientific goals of the members of the MCT Program are:
Our members have a wide range of expertise essential for identifying molecular targets by gene expression profiling as well as developing innovative cancer therapeutics by computational and high-throughput screening approaches and validating them by RNA interference and other molecular techniques. The members are also experts in medicinal chemistry, pharmacokinetics and pharmacodynamics. Our program is focused on the development of new cancer therapeutics from target identification through drug screening to proof of concept for clinical trials. The programmatic goals of the MCT Program are:
The MCT Program has three overlapping areas of focus: new target and drug discovery, molecular and biological analysis of existing drugs, the re-use of old drugs. MCT Program not only develops cytotoxic drugs but also targeted drugs. The program aims at designing drugs or drug regimens that based on regress molecular, structural and experimental analysis of novel cancer targets. The MCT Program also attempts to discover uses for old, FDA approved drugs in new cancers or cancer subtypes.
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005